An Introduction to Newer PET Diagnostic Agents and Related Therapeutic Radiopharmaceuticals

With new radiopharmaceuticals constantly in development, the field of nuclear medicine is ever evolving. This continuing education article reviews some of the newer, less frequently used radiopharmaceuticals for PET diagnostic imaging and related therapeutic protocols. The radiopharmaceuticals discussed include U.S. Food and Drug Administration-approved tracers as well as tracers that are in clinical trials and have yet to obtain Food and Drug Administration approval. This article contains straightforward information on each tracer discussed, including disease process imaged or treated, half-life, energy, primary uses, basic protocols, distribution, and side effects. Although not all tracers may be available in rural locations, this information can be helpful in determining future patient-care offerings.